Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

bioAffinity Technologies (BIAF) Non Operating Income (2022 - 2026)

bioAffinity Technologies has reported Non Operating Income over the past 5 years, most recently at -$13634.0 for Q1 2026.

  • Quarterly Non Operating Income rose 44.54% to -$13634.0 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was -$4.3 million through Mar 2026, down 4855.97% year-over-year, with the annual reading at -$4.3 million for FY2025, 5644.49% down from the prior year.
  • Non Operating Income was -$13634.0 for Q1 2026 at bioAffinity Technologies, down from $2678.0 in the prior quarter.
  • Over five years, Non Operating Income peaked at $42764.0 in Q2 2023 and troughed at -$2.8 million in Q3 2025.
  • The 5-year median for Non Operating Income is -$18703.0 (2024), against an average of -$390812.5.
  • The largest YoY upside for Non Operating Income was 113.16% in 2025 against a maximum downside of 11183.35% in 2025.
  • A 5-year view of Non Operating Income shows it stood at -$1.1 million in 2022, then skyrocketed by 97.52% to -$28466.0 in 2023, then increased by 28.53% to -$20344.0 in 2024, then soared by 113.16% to $2678.0 in 2025, then plummeted by 609.11% to -$13634.0 in 2026.
  • Per Business Quant, the three most recent readings for BIAF's Non Operating Income are -$13634.0 (Q1 2026), $2678.0 (Q4 2025), and -$2.8 million (Q3 2025).